Crossmark

PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling

Published Online: 2022-05-04

Published Print: 2023-04

Authors

Xu, Biao

Li, Jingyuan

Xu, Dehong

Ran, Qijie https://orcid.org/0000-0002-7103-4705
License Information

Text and Data Mining valid from 2022-05-04

Version of Record valid from 2022-05-04
More Information

Article History

Received: 17 February 2022

Accepted: 4 April 2022

First Online: 4 May 2022

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current